phase 1_completion
saveDaiichi Sankyo Co Ltd — raludotatug deruxtecan (Phase I Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Kidney Cancer (Renal Cell Cancer), Ovarian Cancer, Renal Cell Carcinoma
Data sources
globaldata
Found something off?
same company · ±60 days · 3
- patent expirylaninamivir: Daiichi Sankyo Co Ltd — laninamivir (Constraining Patent Expiry (Japan))Apr 24, 2026
- drug expirylaninamivir: Daiichi Sankyo Co Ltd — laninamivir (Drug Expiry (Japan))Apr 24, 2026
- approvalquizartinib dihydrochloride: VANFLYTA (QUIZARTINIB DIHYDROCHLORIDE) — FDA approvalApr 13, 2026
comments(0)
5-min edit window · permanent after that